Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 16, 2007, Pages 3906-3920

  Lin, Wenwei ^a   Buolamwini, John K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 BIS(DIETHYLAMINO) 4,8 DIHEPTAMETHYLENE IMINOPYRIMIDO[5,4 D]PYRIMIDINE; DIPYRIDAMOLE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; ETHANOLAMINE; ETHANOLAMINE DERIVATIVE; HYDROXYL GROUP; LIDOFLAZINE; NITROBENZYLTHIOINOSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN K 562; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; DIPYRIDAMOLE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548057625     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070311l     Document Type: Article

References (57)

1. Griffith, D. A.; Jarvis, S. M. Nucleoside and Nucleobase Transport Systems of Mammalian Cells. Biochim. Biophys. Acta 1996, 1286, 153-181.
2. Kong, W.; Engel, K.; Wang, J. Mammalian Nucleoside Transporters. Curr. Drug Metab. 2004, 5, 63-84.
3. Baldwin, S. A.; Beal, P. R.; Yao, S. Y. M.; King, A. E.; Cass, C. E.; Young, J. D. The Equilibrative Nucleoside Transporter Family, SLC29. Pfluegers Arch. 2004, 447, 735-743.
4. Gray, J. H.; Owen, R. P.; Giacomini, K. M. The Concentrative Nucleoside Transporter Family, SLC28. Pflugers Arch. 2004, 447, 728-734.
5. Fritzgerald, G. A. Dipyridamole. N. Engl. J. Med. 1987, 316, 1247-1257.
6. Abd-Elfattah, A. S.; Wechsler, A. S. Separation between Ischemic and Reperfusion Injury by Site Specific Entrapment of Endogenous Adenosine and Inosine Using NBMPR and EHNA. J. Cardiovasc. Surg. 1994, 9 (Suppl.), 387-396.
7. Abd-Elfattah, A.-S. A.; Hoehner, J.; Wechsler, A. S. Identification of Nucleoside Transport Binding Sites in the Human Myocardium. Mol. Cell. Biochem. 1998, 180, 105-110.
8. Van Belle, H. Nucleoside Transport Inhibition: A Therapeutic Approach to Cardioprotection via Adenosine? Cardiovasc. Res. 1993, 27, 68-76.
9. Deckert, J.; Morgan, P. F.; Marangos, P. J. Adenosine Uptake Site Heterogeneity in the CNS? Uptake Inhibitors as Probes and Potential Neuropharmaceuticals. Life Sci. 1988, 42, 1331-1345.
10. Geiger, J. D.; Parkinson, F. E.; Kowaluk, E. A. Regulators of Endogenous Adenosine Levels as Therapeutic Agents. In Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997; pp 55-84.
11. Ohta, A.; Stkovski, M. The Role of G-Protein-Coupled Adenosine Receptors in Downregulation of Inflammation and Protection from Tissue Damage. Nature 2001, 414, 916-920.
12. Tew, K. D.; Houghton, P. J.; Houghton, J. A. Preclinical and Clinical Modulation of Anticancer Drugs; CRC Press: Boca Raton, FL, 1993; Chapter 7.
13. Buolamwini, J. K. Nucleoside Transport Inhibitors: Structure-Activity Relationships and Potential Therapeutic Applications. Curr. Med. Chem. 1997, 4, 35-66.
14. Williams, E. F. Radioreceptor Characterization of Cardiovascular Nucleoside Transporters. SAAS Bull. Biochem. Biotechnol. 1996, 9, 51-56.
15. Hoehner, J.; Wechsler, A. S.; Abd-Elfattah, A.-S. Nucleoside Transport in the Human Myocardium. Dev. Cardiovasc. Med. 1996, 181, 209-218.
16. Zhu, Z.; Furr, J.; Buolamwini; J. K. Synthesis and Flow Cytometric Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline Conformationally Constrained Analogs of Nitrobenzylmercaptopurine Riboside (NB-MPR) Designed for Probing Its Conformation When Bound to the es Nucleoside Transporter. J. Med. Chem. 2003, 46, 831-837.
17. Gupte, A.; Buolamwini, J. K. Novel Halogenated Nitrobenzylthioinosine Analogs as es Nucleoside Transporter Inhibitors. Bioorg. Med. Chem. 2004, 14, 2257-2260.
18. Hammond, J. R. Interaction of a Series of Draflazine Analogues with Equilibrative Nucleoside Transporters: Species Differences and Transporter Subtype Selectivity. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 373-382.
19. Cass, C. E.; Muzik, H.; Paterson, R. P. Combination Therapy of Mouse Leukemia L1210 by 1-β-D-Arabinofuranosylcytosine and 6-[(4-Nitrobenzyl)thio]-9-β-D-Ribofuranosylpurine. Cancer Res. 1975, 35, 1187-1193.
20. Benedict, W. F.; Baker, M. S.; Haroun, L.; Choi, E.; Ames, B. N. Mutagenicity of Cancer Chemotherapeutic Agents in the Salmonella/ Microsome Test. Cancer Res. 1977, 37, 2209-2213.
21. Elion, G. B. Biochemistry and Pharmacology of Purine Analogs. Fed. Proc. 1967, 26, 898-904.
22. 1 Receptor Activation. J. Pharmacol. Exp. Ther. 1994, 268, 90-96.
23. Mustafa, S. J.; Nakagawa, Y. Relaxing Effects of Dipazep and Lidoflazine in Dog Cerebral and Renal Arteries Independent of Adenosine. Pharmacology 1988, 37, 75-84.
24. Kates, R. A.; Dorsey, L. M.; Kaplan, J. A.; Hatcher, C. R.; Guyton, R. A. Pretreatment with Lidoflazine, a Calcium-Channel Blocker. J. Thorac. Cardiovasc. Surg. 1983, 85, 278-286.
25. Harker, L. A.; Kadatz, R. A.; Gmbh, K. T. Mechanism of Action of Dipyridamole. Thromb. Res. 1983, Suppl. IV, 39-46.
26. Rivey, M. P.; Alexander, M. R.; Taylor, J. W. Dipyridamole: A Critical Evaluation. Drug Intell. Clin. Pharm. 1984, 18, 869-880.
27. Weber, G.; Prajda, N. Targeted and Non-targeted Actions of Anti-cancer Drugs. Adv. Enzyme Regul. 1994, 34, 71-89.
28. Boyer, C. R.; Karjian, P. L.; Wahl, G. M.; Pegram, M.; Neuteboom, S. T. C. Nucleoside Transport Inhibitors, Dipyridamole and p-Nitrobenzylthioinosine, Selectively Potentiate the Antitumor Activity of NB1011. Anti-Cancer Drugs 2002, 13, 29-36.
29. Grem, J. L. Biochemical Modulation of Fluorouracil by Dipyridamole: Preclinical and Clinical Experience. Semin. Oncol. 1992, 19 (Suppl. 3), 56-65.
30. Smith, P. G.; Marshman, E.; Newell, D. R.; Curtin, N. J. Dipyridamole Potentiates the in Vitro Activity of MTA (LY231514) by Inhibition of Thymidine Transport. Br. J. Cancer 2000, 82, 924-930.
31. Sherman, I. W. Biochemistry of Plasmodium (Malarial Parasites). Microbiol. Rev. 1979, 43, 453-495.
32. Gero, A. M.; O'Sullivan, W. J. Purines and Pyrimidines in Malarial Parasites. Blood Cells 1990, 16, 467-484.
33. el Kouni, M. H. Potential Chemotherapeutic Targets in the Purine Metabolism of Parasites. Pharmacol. Ther. 2003, 99, 283-309.
34. Carter, N. S.; Landfear, S. M.; Ullmam, B. Nucleoside Transporters of Parasitic Protozoa. Trends Parasitol. 2001, 17, 145.
35. el Kouni, M. H.; Guarcello, V.; Al Safarjalani, O. N.; Naguib, F. N. M. Metabolism and Selective Toxicity of 6-Nitrobenzylthioinosine in Toxoplasma gondii. Antimicrob. Agents Chemother. 1999, 43, 2437-2443.
36. Akaki, M.; Nakano, Y.; Ito, Y.; Nagayasu, E.; Aikawa, M. Effects of Dipyridamole on Plasmodium falciparum-lnfected Erythrocytes. Parasitol. Res. 2002, 88, 1044-1050.
37. Kadatz, R. The Pharmacology of 2,6-bis(diethanolamino)-4,8-dipiperidino- pyrimido-(5,4-d)-pyrimidine, a new compound with coronary dilatory properties. Arzneim.-Forsch. 1959, 9, 39-45.
38. Fischer, F. G.; Roch, W.; Roch, J.; Kottler, A. Substituted Pyrimido[5,4-d]-pyrimidines. U.S. Patent 3,031,450, 1962.
39. Roch, J.; Beisenherz, G.; an der Riss, B. Basic-Substituted Pyrimido[5,4-d]-pyrimidines. U.S. Patent 3,074,928, 1963.
40. Kaminsky, D.; Lutz, W. B.; Lazarus, S. Some Congeners and Analogs of Dipyridamole. J. Med. Chem. 1966, 9, 610-612.
41. Roch, J.; Erich, M.; Narr, B.; Machleidt, H. S African Patent 6,-905,504, 1970.
42. Northen, J. S.; Boyle, F. T.; Clegg, W.; Curtin, N. J.; Edwards, A. J.; Griffin, R. J.; Golding, B. T. Controlled Stepwise Conversion of 2,4,6,8-Tetrachloropyrimido-[5,4-d]pyrimidine into 2,4,6,8- Tetrasubstituted Pyrimido[5,4-d]-pyrimidines. J. Chem. Soc., Perkin Trans. 1 2002, 108-115.
43. 1-Acid Glycoprotein. J. Med. Chem. 2004, 47, 4905-4922.
44. 6-(4-nitrobenzyl)-5′- thioadenosine): Flow Cytometry Probes for the Es Transporter Elements of the Plasma Membrane. Nucleosides Nucleotides 1994, 13, 737-751.
45. 3H]Nitrobenzylthioinosine Binding Site. Mol. Pharmacol. 1991, 39, 771-779.
46. 3H]Uridine Influx Studies. J. Neurochem. 1992, 59, 1363-1371.
47. 3H)Nitroben- zylthioinosine Binding Sites at the Human Parietal Cortex and Erythrocyte Adenosine Transporter: A Comparison. Life Sci. 1994, 55, 1675-1682.
48. Vargas, F.; Rivas, C.; Fuentes, A.; Tse, Cheng, A.; Velutini, G. The Photochemistry of Dipyridamole. J. Photochem. Photobiol. 2002, 153, 237-243.
49. Boleti, H.; Coe, I. R.; Baldwin, S. A.; Young, J. D.; Cass, C. E. Molecular Identification of the Equilibrative NBMPR-sensitive (es) Nucleoside Transporter and Demonstration of an Equilibrative NBMPR-insensitive (ei) Transport Activity in Human Erythroleukemia (K562) Cells. Neuropharmacology 1997, 36, 1167-1179.
50. Huang, Y.; Anderle, P.; Bussey, K. J.; Barbacioru, C.; Shankavaram, U.; Dai, Z.; Reinhold, W. C.; Papp, A.; Weinstein, J. N.; Sadee, W. Membrane Transporters and Chennels: Role of the Transportome in Cancer Chemosensitivity and Chemoresistance. Cancer Res. 2004, 64, 4294-4301.
51. Addo, J. K.; Buolamwini, J. K. Design, Synthesis, and Evaluation of 5′-S-Aminoethyl-N(6)-azidobenzyl-5′-thioadenosine Biotin Conjugate: A Bifunctional Photoaffinity Probe for the es Nucleoside Transporter. Bioconjugate Chem. 2004, 15, 536-540.
52. Huang, M.; Wang, Y.; Cogut, S. B.; Mitchell, B. S.; Graves, L. M. Inhibition of Nucleoside Transport by Protein Kinase Inhibitors. J. Pharmacol. Exp. Ther. 2003, 304, 753-760.
53. Huang, M.; Wang, Y.; Collins, M.; Gu, J. J.; Mitchell, B. S.; Graves, L. M. Inhibition of Nucleoside Transport by p38 MARK Inhibitors. J. Biol. Chem. 2002, 277, 28364-28367.
54. Agoston, G. E.; Wu, J. H.; Izenwasser, S.; George, C.; Katz, J.; Kline, R. H.; Newman, A. H. Novel N-Substituted 3α-[Bis(4′-fluorophenyl)- methoxyltropane Analogs: Selective Ligands for the Dopamine Transporter. J. Med. Chem. 1997, 40, 4329-4339.
55. 3,8]undecane Compounds. U.S. Patent 4,557,865, 1985.
56. Williams, D. E.; Craig, K. S.; Patrick, B.; McHardy, L. M.; Soest, R. V.; Roberge, M.; Andersen, R. J. Motuporamines, Anti-Invasion and Anti-Angiogenic Alkaloids from the Marine Sponge Xestospongia exigua (Kirkpatrick): Isolation, Structure Elucidation, Analog Synthesis, and Conformational Analysis. J. Org. Chem. 2002, 67, 245-258.
57. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.